BP
MIRM icon

Ballentine Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Ballentine Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$391K Buy
3,339
+15
+0.5% +$1.51K ﹤0.01% 659
2026
Q1 		$307K Hold
3,324
– – ﹤0.01% 729
2025
Q4 		$263K Sell
3,324
-256
-7% -$18.4K ﹤0.01% 787
2025
Q3 		$262K Buy
+3,580
New +$228K ﹤0.01% 787

Other funds holding MIRM

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
SAM
Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return

Ballentine Partners's MIRM Position: Q2 2026 in Review

Ballentine Partners increased its Mirum Pharmaceuticals (MIRM) stake by 0.45% in Q2 2026, buying an estimated $1.51K and bringing the position to 3,339 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #659.

Ballentine Partners first reported a position in MIRM in Q3 2025 and has held it in 4 quarters since. 22 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Ballentine Partners held 3,339 shares of Mirum Pharmaceuticals worth $391K as of Q2 2026.
  • Ballentine Partners bought 15 Mirum Pharmaceuticals shares in Q2 2026, an estimated $1.51K.
  • Mirum Pharmaceuticals made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #659 holding.
  • Ballentine Partners first reported a position in Mirum Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 22 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.